Health effects of the Federal Bureau of Prisons tobacco ban

BMC Pulmonary Medicine

Robert J Goldberg¹  Melissa Foster²  Sandra Howard⁶  Herbert Beam⁶  Jennifer G Clarke⁴  Stephen J Krinzman⁵  Joseph R DiFranza²  Bartolome R Celli³  Stephen A Martin⁷ 

[1] Department of Quantitative Health Sciences, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA, 01655, USA;Department of Family Medicine and Community Health, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA, 01655, USA;Harvard Medical School, Brigham and Women’s Hospital, Pulmonary and Critical Care Medicine, 75 Francis Street, Boston, MA, 02115, USA;The Warren Alpert Medical School of Brown University, 111 Brewster Street, CPCP 2nd floor, Pawtucket, RI, 02860, USA;Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA, 01655, USA;Federal Bureau of Prisons, Federal Medical Center, Devens, P.O. Box 880, Ayer, MA, 01432, USA;Department of Family Medicine and Community Health, University of Massachusetts Medical School, Barre Family Health Center, 151 Worcester Road, Barre, MA, 01005, USA

关键词: Health services;    Addiction;    Nicotine;    Tobacco;    Pulmonary function tests;    Biomarkers;    Pathophysiology;    Asthma;    Chronic Obstructive Pulmonary Disease;    Pulmonary disease;   

Others  :  1136345
DOI  :  10.1186/1471-2466-12-64

 received in 2012-04-12, accepted in 2012-10-08,  发布年份 2012

【 摘 要 】

Background

Tobacco smoking remains the leading cause of preventable death in America, claiming 450,000 lives annually. Chronic Obstructive Pulmonary Disease, caused by smoking in the vast majority of cases, became the third leading cause of death in the U.S. in 2008. The burden of asthma, often exacerbated by tobacco exposure, has widespread clinical and public health impact. Despite this considerable harm, we know relatively little about the natural history of lung disease and respiratory impairment in adults, especially after smoking cessation.

Methods/Design

Our paper describes the design and rationale for using the 2004 Federal Bureau of Prisons tobacco ban to obtain insights into the natural history of respiratory diseases in adult men and women of different races/ethnicities who are imprisoned in federal medical facilities. We have developed a longitudinal study of new prison arrivals, with data to be collected from each participant over the course of several years, through the use of standardized questionnaires, medical chart reviews, lung function tests, six-minute walk tests, and stored serum for the analysis of present and future biomarkers. Our endpoints include illness exacerbations, medication and health services utilization, lung function, serum biomarkers, and participants’ experience with their health and nicotine addiction.

Discussion

We believe the proposed longitudinal study will make a substantial contribution to the understanding and treatment of respiratory disease and tobacco addiction.

【 授权许可】

   
2012 Martin et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Schroeder SA, Warner KE: Don’t forget tobacco. N Engl J Med 2010, 363(3):201-204.
• [2]Curfman GD, Morrissey S, Drazen JM: Tobacco, public health, and the FDA. Ibid 2009.
• [3]Vital signs: current cigarette smoking among adults aged >/=18 years--United States, 2005–2010 MMWR Morbidity and mortality weekly report 2011, 60(35):1207-1212.
• [4]Minino AM, Xu J, Kochanek KD: Deaths: final data for 2008. Natl Vital Stat Reports 2010, 59(2):1-52.
• [5]Wier LM, Elixhauser A, Pfuntner A, Au DH: Overview of Hospitalizations among Patients with COPD. Rockville, MD: Agency for Healthcare Research and Quality; 2008. HCUP Statistical Brief #106
• [6]Oberg M, Jaakkola MS, Woodward A, Peruga A, Pruss-Ustun A: Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. Lancet 2012, 377(9760):139-146.
• [7]McLeish AC, Zvolensky MJ: Asthma and cigarette smoking: a review of the empirical literature. The Journal of asthma: official journal of the Association for the Care of Asthma 2010, 47(4):345-361.
• [8]Tamimi A, Serdarevic D, Hanania NA: The effects of cigarette smoke on airway inflammation in asthma and COPD: Therapeutic implications. Respiratory Medicine 2012, 106(3):319-328.
• [9]Fletcher C, Peto R, Tinker C, Speizer FE: The natural history of chronic bronchitis and emphysema: an eight-year study of early chronic obstructive lung disease in working men in London.. Oxford; New York: Oxford University Press; 1976. http://utas.libguides.com/content.php?pid=27520&sid=274581 webcite
• [10]Fletcher C, Peto R: The natural history of chronic airflow obstruction. Br Med J 1977, 1(6077):1645-1648.
• [11]Tashkin DP, Murray RP: Smoking cessation in chronic obstructive pulmonary disease. Respiratory Medicine 2009, 103(7):963-974.
• [12]Fletcher C, Peto R, Tinker C, Speizer FE: The natural history of chronic bronchitis and emphysema: an eight-year study of early chronic obstructive lung disease in working men in London. 148
• [13]Agusti A, Vestbo J: Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 184(5):507-513.
• [14]Kohansal R, Soriano JB, Agusti A: Investigating the natural history of lung function: facts, pitfalls, and opportunities. Chest 2009, 135(5):1330-1341.
• [15]Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS: Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000, 161(2 Pt 1):381-390.
• [16]Tashkin DP, Rennard S, Taylor Hays J, Lawrence D, Marton JP, Lee TC: Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients. Respir Med 2011, 105(11):1682-1690.
• [17]Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, et al.: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363(12):1128-1138.
• [18]Tashkin DP: Frequent exacerbations of chronic obstructive pulmonary disease--a distinct phenotype? Ibid1183-1184.
• [19]Reilly JJ: COPD and declining FEV1–time to divide and conquer? Ibid 2008, 359(15):1616-1618.
• [20]Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, et al.: Changes in forced expiratory volume in 1 second over time in COPD. Ibid 2011, 365(13):1184-1192.
• [21]Kauffman RM, Ferketich AK, Wewers ME: Tobacco policy in American prisons, 2007. Tob Control 2008, 17(5):357-360.
• [22]Cropsey KL, Kristeller JL: The effects of a prison smoking ban on smoking behavior and withdrawal symptoms. Addict Behav 2005, 30(3):589-594.
• [23]Kauffman RM, Ferketich AK, Murray DM, Bellair PE, Wewers ME: Tobacco use by male prisoners under an indoor smoking ban. Nicotine Tob Res 2011, 13(6):449-456.
• [24]Thibodeau L, Jorenby DE, Seal DW, Kim SY, Sosman JM: Prerelease intent predicts smoking behavior postrelease following a prison smoking ban. Ibid 2010, 12(2):152-158.
• [25]Thibodeau L, Seal DW, Jorenby DE, Corcoran K, Sosman JM: Perceptions and Influences of a State Prison Smoking Ban. J Correct Health Carein press
• [26]Fletcher C, Peto R: The natural history of chronic airflow obstruction. Br Med J 1977, 1(6077):1645-1648.
• [27]Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, et al.: Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011, 365(13):1184-1192.
• [28]Pinto-Plata V, Casanova C, Mullerova H, de Torres JP, Corado H, Varo N, Cordova E, Zeineldine S, Paz H, Baz R, et al.: Inflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD. Respir Res 2012, 13(1):71. BioMed Central Full Text
• [29]Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, et al.: Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012, 7(5):e37483.
• [30]Lincoln T, Tuthill RW, Roberts CA, Kennedy S, Hammett TM, Langmore-Avila E, Conklin TJ: Resumption of smoking after release from a tobacco-free correctional facility. J Correct Health Care 2009, 15(3):190-196.
• [31]Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, Koepsell TD: Release from prison–a high risk of death for former inmates. N Engl J Med 2007, 356(2):157-165.
• [32]Quick Facts about the Bureau of Prisons. http://www.bop.gov/news/quick.jsp webcite
• [33]Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, et al.: Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation 2011, 123(4):e18-e209.
• [34]Lee PN, Fry JS: Systematic review of the evidence relating FEV1 decline to giving up smoking. BMC medicine 2011, 8:84. Vestbo J et al
• [35]Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350(10):1005-1012.
• [36]Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, et al.: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31(2):416-469.
• [37]NIH/NHLBI. http://www.nhlbi.nih.gov/funding/policies/repos-gl.htm webcite
• [38]Ziedonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE, Audrain-McGovern J, Breslau N, Brown RA, George TP, Williams J, et al.: Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res 2008, 10(12):1691-1715.
• [39]Williams JM: Eliminating Tobacco Use in Mental Health Facilities: Patients’ Rights, Public Health, and Policy Issues. JAMA 2008, 299(5):571-573.
• [40]Clarke JG, Martin RA, Stein L, Lopes CE, Mello J, Friedmann P, Bock B: Working Inside for Smoking Elimination (Project W.I.S.E.) study design and rationale to prevent return to smoking after release from a smoke free prison. BMC Publ Health 2011, 11:767. BioMed Central Full Text